Glyphosate CTA

Informazioni principali

  • Nome commerciale:
  • Glyphosate CTA
  • Forma farmaceutica:
  • SL concentrato solubile in acqua
  • Utilizzare per:
  • Piante
  • Tipo di medicina:
  • Agrochimico

Documenti

  • per i professionisti:
  • Il foglio illustrativo per questo prodotto non è al momento disponibile, é possibile inviare una richiesta al nostro Servizio Clienti ed essere avvisati nel momento in cui è disponibile sulla nostra piattaforma.


    Richiedi il foglio illustrativo per i professionisti.

Localizzazione

  • Disponibile in:
  • Glyphosate CTA
    Svizzera
  • Lingua:
  • italiano

Informazioni terapeutiche

  • Gruppo terapeutico:
  • Erbicida

Altre informazioni

Status

  • Fonte:
  • UFAG - Ufficio federale dell'agricoltura. OFAG - Office fédéral de l'agriculture. BLW - Bundesamt für Landwirtschaft.
  • Numero dell'autorizzazione:
  • W-4756
  • Ultimo aggiornamento:
  • 18-11-2018

Foglio illustrativo: composizione, posologia, indicazioni, interazioni, gravidanza, allattamento, effetti indesiderati, controindicazioni

Denominazione commerciale: Glyphosate CTA

Elenco dei prodotti fitosanitari (stato: 06.11.2018)

Categoria di

prodotti:

Titolare dell'autorizzazione:

Numero federale di

omologazione:

Erbicida

Omya (Schweiz) AG

W-4756

Principio:

Tenore:

Codice di formulazione:

Principio attivo:

Glifosato

31 % 360 g/l

[Pari a 41% di Glifosato-isopropile sale di

ammonio (476 g/l)]

SL concentrato solubile in

acqua

Applicazioni

A

Coltura

Agente

patogeno/Efficacia

Dosaggio

Restrizioni

B Mora

Dicotiledoni annuali

(malerbe)

Gramigna

Monocotiledoni

annuali (malerbe).

Dose: 2 - 3 l/ha

1, 2

B Mora

Dicotiledoni

pluriennali (malerbe)

Monocotiledoni

perenni (malerbe)

Dose: 4 - 10 l/ha

1, 2

Frutta a granelli

Frutta a nocciolo

Dicotiledoni annuali

(malerbe)

Gramigna

Monocotiledoni

annuali (malerbe).

Dose: 2 - 3 l/ha

1, 2

Frutta a granelli

Frutta a nocciolo

Dicotiledoni

pluriennali (malerbe)

Monocotiledoni

perenni (malerbe)

Dose: 4 - 10 l/ha

1, 2

W Vite [Piantagioni in produzione ]

Dicotiledoni annuali

(malerbe)

Gramigna

Monocotiledoni

annuali (malerbe).

Dose: 2 - 3 l/ha

1, 2

A

Coltura

Agente

patogeno/Efficacia

Dosaggio

Restrizioni

W Vite [Piantagioni in produzione ]

Dicotiledoni

pluriennali (malerbe)

Monocotiledoni

perenni (malerbe)

Dose: 4 - 10 l/ha

1, 2

G Maggese

Dicotiledoni annuali

(malerbe)

Gramigna

Monocotiledoni

annuali (malerbe).

Dose: 2 - 3 l/ha

1, 3

G Maggese

Dicotiledoni

pluriennali (malerbe)

Monocotiledoni

perenni (malerbe)

Dose: 4 - 10 l/ha

1, 3

Maggese

Dicotiledoni annuali

(malerbe)

Gramigna

Monocotiledoni

annuali (malerbe).

Dose: 2 - 3 l/ha

1, 3

Maggese

Dicotiledoni

pluriennali (malerbe)

Monocotiledoni

perenni (malerbe)

Dose: 4 - 10 l/ha

1, 3

Mais

Dicotiledoni annuali

(malerbe)

Gramigna

Monocotiledoni

annuali (malerbe).

Dose: 2 - 3 l/ha

Applicazione: Alla semina.

1, 4, 5

Mais

Dicotiledoni

pluriennali (malerbe)

Monocotiledoni

perenni (malerbe)

Dose: 4 - 10 l/ha

Applicazione: Alla semina.

1, 4, 5

Prati e pascoli

Dicotiledoni

(malerbe)

Monocotiledoni

(malerbe)

Dose: 4 - 10 l/ha

Applicazione: Trattamento su

tutta la superficie prima della

risemina.

1, 3

A

Coltura

Agente

patogeno/Efficacia

Dosaggio

Restrizioni

Prati e pascoli

Dicotiledoni

(malerbe)

Monocotiledoni

(malerbe)

Concentrazione: 0.5 - 1.5 %

Termine d'attesa: 3 Settimane

Applicazione: Con

vaporizzatore a zaino.

1, 6, 7

Prati e pascoli

Dicotiledoni

(malerbe)

Monocotiledoni

(malerbe)

Concentrazione: 5 - 10 %

Termine d'attesa: 3 Settimane

Applicazione: Con

vaporizzatori manuali.

1, 6, 7

Alberi e arbusti (al di fuori della

foresta)

Rose

Dicotiledoni annuali

(malerbe)

Gramigna

Monocotiledoni

annuali (malerbe).

Dose: 2 - 3 l/ha

1, 2

Alberi e arbusti (al di fuori della

foresta)

Rose

Dicotiledoni

pluriennali (malerbe)

Monocotiledoni

perenni (malerbe)

Dose: 4 - 10 l/ha

1, 2

Maggese

Dicotiledoni annuali

(malerbe)

Gramigna

Monocotiledoni

annuali (malerbe).

Dose: 2 - 3 l/ha

1, 3

Maggese

Dicotiledoni

pluriennali (malerbe)

Monocotiledoni

perenni (malerbe)

Dose: 4 - 10 l/ha

1, 3

Vivai forestali

Dicotiledoni annuali

(malerbe)

Gramigna

Monocotiledoni

annuali (malerbe).

Dose: 2 - 3 l/ha

1, 2

Vivai forestali

Dicotiledoni

pluriennali (malerbe)

Monocotiledoni

perenni (malerbe)

Dose: 4 - 10 l/ha

1, 2

N Lungo le strade nazionali e

cantonali

Dicotiledoni annuali

(malerbe)

Gramigna

Monocotiledoni

Dose: 2 - 3 l/ha

1, 8

A

Coltura

Agente

patogeno/Efficacia

Dosaggio

Restrizioni

annuali (malerbe).

Lungo le strade nazionali e

cantonali

Dicotiledoni

pluriennali (malerbe)

Monocotiledoni

perenni (malerbe)

Dose: 4 - 10 l/ha

1, 8

Scarpate e strisce verdi lungo le

vie di comunicazione

(conformemente ORRPChim)

Dicotiledoni annuali

(malerbe)

Gramigna

Monocotiledoni

annuali (malerbe).

Dose: 2 - 3 l/ha

1, 8

Scarpate e strisce verdi lungo le

vie di comunicazione

(conformemente ORRPChim)

Dicotiledoni

pluriennali (malerbe)

Monocotiledoni

perenni (malerbe)

Dose: 4 - 10 l/ha

1, 8

Ö Superficie coltiva aperta

Convolvulaceae

Gramigna

Romice comune

Stoppione

Concentrazione: 5 - 10 %

Applicazione: Con

vaporizzatori manuali (senza

vaporizzatore a zaino).

1, 9

Ö Superficie inerbita

Romice comune

Stoppione

Concentrazione: 5 - 10 %

Applicazione: Con

vaporizzatori manuali (senza

vaporizzatore a zaino).

1, 6, 9

Restrizioni e osservazioni:

Non devono esserci precipitazioni durante almeno 6 ore dopo il trattamento.

Trattamento al più tardi entro fine agosto. Le parti verdi delle piante coltivate non devono entrare

in contatto con l'erbicida.

Trattamento al più tardi fino a 2 settimane prima della semina o della piantagione.

La dose si riferisce alla superficie effettiva da trattare.

Trattamento della superficie non lavorata tra le file durante la semina a bande fresate.

Pascolo o sfalcio (foraggio fresco o conservato) al più presto 3 settimane dopo il trattamento.

Eccezione: per gli animali non in lattazione il termine di attesa è di 2 settimane.

Trattamento pianta per pianta.

Conformemente all'ordinanza sulla riduzione dei rischi inerenti ai prodotti chimici (ORRPChim):

Soltanto trattamenti pianta per pianta su piante problematiche, che non possono essere combattute

efficacemente con altre misure.

Per il trattamento pianta per pianta secondo l'ordinanza sui pagamenti diretti (OPD).

Caratterizzazione di pericolo:

Tenere fuori dalla portata dei bambini.

EUH 401 Per evitare rischi per la salute umana e per l'ambiente, seguire le istruzioni per l'uso.

H411 Tossico per gli organismi acquatici con effetti di lunga durata.

SP 1 Non contaminare l'acqua con il prodotto o il suo imballaggio.

Simboli e indicazioni di pericolo:

Identificatore chiave

GHS09

Simbolo

Indicazione di pericolo Pericoloso per l'ambiente acquatico

In caso di dubbio valgono soltanto i documenti originali dell'omologazione. La menzione di un prodotto,

principio attivo o di una ditta non rappresenta alcuna raccomandazione.

12-1-2019

Pest categorisation of Pseudopityophthorus minutissimus and P. pruinosus

Pest categorisation of Pseudopityophthorus minutissimus and P. pruinosus

Published on: Fri, 11 Jan 2019 The Panel on Plant Health performed a pest categorisation of Pseudopityophthorus minutissimus and Pseudopityophthorus pruinosus, two well‐defined insect species in the family Curculionidae, subfamily Scolytinae (Insecta: Coleoptera). They can be identified using taxonomic keys. P. minutissimus is present in parts of Canada and the USA, and P. pruinosus is present in parts of the USA, Guatemala, Honduras and Mexico. The main host plants of the two species are Quercus spp., ...

Europe - EFSA - European Food Safety Authority EFSA Journal

12-1-2019

Assessment of the application for renewal of authorisation of Lantharenol® (lanthanum carbonate octahydrate) for cats

Assessment of the application for renewal of authorisation of Lantharenol® (lanthanum carbonate octahydrate) for cats

Published on: Fri, 11 Jan 2019 Lantharenol® is a feed additive consisting of lanthanum carbonate octahydrate. It is currently authorised as a zootechnical additive (decrease in phosphorous excretion via urine) for cats; this opinion concerns the renewal of the authorisation. In 2007, the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) adopted an opinion on the safety and efficacy of Lantharenol® as a feed additive for cats. The applicant has provided data demonstrating th...

Europe - EFSA - European Food Safety Authority EFSA Journal

19-12-2018

Pest categorisation of Phyllosticta solitaria

Pest categorisation of Phyllosticta solitaria

Published on: Tue, 18 Dec 2018 The European Commission requested EFSA to conduct a pest categorisation of Grapholita prunivora (Lepidoptera: Tortricidae), an oligophagous moth whose larvae feed mostly on leaves and fruit of different Rosaceae including cultivated apples, plums, cherries and pecans. It overwinters in soil and bark crevices of its host plants. G. prunivora has reliable identification methods, both for adults and immature stages. It occurs in North America, where it can impact pome and sto...

Europe - EFSA - European Food Safety Authority EFSA Journal

29-11-2018

Glyphosate: ANSES launches a comparative assessment with the available alternatives

Glyphosate: ANSES launches a comparative assessment with the available alternatives

Following the five-year re-approval of this active substance at European level in December 2017, ANSES is reassessing marketing authorisations for products containing glyphosate. For products for which an application for authorisation or re-authorisation has been submitted, the Agency will carry out a comparative assessment with the available alternatives. For each glyphosate-based product, all uses for which there is an alternative that meets the substitution criteria will therefore be prohibited.

France - Agence Nationale du Médicament Vétérinaire

20-11-2018

Pest categorisation of non‐EU Monochamus spp.

Pest categorisation of non‐EU Monochamus spp.

Published on: Mon, 19 Nov 2018 The Panel on Plant Health performed a pest categorisation of non‐EU Monochamus spp., a well‐defined insect genus in the family Cerambycidae (Insecta: Coleoptera). Species can be identified using taxonomic keys at national and regional level, and DNA barcoding. Two online world catalogues exist for the genus. The genus includes about one hundred species and many subspecies colonising conifers and non‐conifer trees in many areas in the world. The non‐EU species are listed in...

Europe - EFSA - European Food Safety Authority Publications

15-11-2018

Assessment of genetically modified maize MZHG0JG for food and feed uses, import and processing under Regulation (EC) No 1829/2003 (application EFSA‐GMO‐DE‐2016‐133)

Assessment of genetically modified maize MZHG0JG for food and feed uses, import and processing under Regulation (EC) No 1829/2003 (application EFSA‐GMO‐DE‐2016‐133)

Published on: Wed, 14 Nov 2018 The scope of application EFSA‐GMO‐DE‐2016‐133 is for food and feed uses, import and processing of genetically modified (GM) maize MZHG0JG in the European Union. Maize MZHG0JG was developed to confer tolerance to the herbicidal active substances glyphosate and glufosinate‐ammonium. The molecular characterisation data and bioinformatic analyses do not identify issues requiring food/feed safety assessment. None of the identified differences in the agronomic/phenotypic and com...

Europe - EFSA - European Food Safety Authority Publications

17-10-2018

Applicability of in silico tools for the prediction of dermal absorption for pesticides

Applicability of in silico tools for the prediction of dermal absorption for pesticides

Published on: Tue, 16 Oct 2018 00:00:00 +0200 Based on the “Human in vitro dermal absorption datasets” published as supporting information to the revised EFSA Guidance on Dermal Absorption, in silico models for prediction of absorption across the skin have been evaluated. For this evaluation, a systematic literature search and review was performed, identifying 288 publications describing mathematical models for prediction of dermal absorption. Eleven models potentially relevant to the regulatory assessm...

Europe - EFSA - European Food Safety Authority Publications

19-9-2018

National dietary survey in 2012‐2016 on the general population aged 1‐79 years in the Netherlands

National dietary survey in 2012‐2016 on the general population aged 1‐79 years in the Netherlands

Published on: Tue, 18 Sep 2018 00:00:00 +0200 During the years 2012‐2016, the Dutch National Food Consumption survey was conducted in the Netherlands. For the survey, a random sample was drawn from consumer panels stratified by age and gender and maintained representative to the population with regard to region, address density and educational level. Complete results were obtained for 4,313 persons (response rate 65%); including toddlers, children, adolescents, adults and elderly. Pregnant or lactating ...

Europe - EFSA - European Food Safety Authority Publications

23-6-2018

Nectar Foods Inc Dba Honey Mama's Issues Allergy Alert on Undeclared Almonds in Oregon Peppermint Cacao Nectar Bar

Nectar Foods Inc Dba Honey Mama's Issues Allergy Alert on Undeclared Almonds in Oregon Peppermint Cacao Nectar Bar

Nectar Foods Inc., DBA Honey Mama's of Portland, Oregon is recalling 79 Sleeves (948 units) of Oregon Peppermint bars, lot code 112918, because it may contain undeclared Almonds. People who have an allergy or severe sensitivity to almonds run the risk of serious or life-threatening allergic reaction if they consume this product.

FDA - U.S. Food and Drug Administration

3-5-2018

FDA Drug Safety Communication: FDA warns of serious immune system reaction with seizure and mental health medicine lamotrigine (Lamictal)

FDA Drug Safety Communication: FDA warns of serious immune system reaction with seizure and mental health medicine lamotrigine (Lamictal)

The Food and Drug Administration (FDA) is warning that the medicine lamotrigine (Lamictal) for seizures and bipolar disorder can cause a rare but very serious reaction that excessively activates the body’s infection-fighting immune system.

FDA - U.S. Food and Drug Administration

25-4-2018

Lamictal (lamotrigine): Drug Safety Communication - Serious Immune System Reaction

Lamictal (lamotrigine): Drug Safety Communication - Serious Immune System Reaction

The FDA is warning that the medicine lamotrigine (Lamictal) for seizures and bipolar disorder can cause a rare but very serious reaction that excessively activates the body’s infection-fighting immune system. This can cause severe inflammation throughout the body and lead to hospitalization and death, especially if the reaction is not diagnosed and treated quickly. As a result, we are requiring a new warning about this risk be added to the prescribing information in the lamotrigine drug labels. The immun...

FDA - U.S. Food and Drug Administration

2-2-2017

Receipt of clinical trial applications (CTA) summer 2017

Receipt of clinical trial applications (CTA) summer 2017

Due to summer holiday the Icelandic Medicines Agency (IMA) will not confirm receipt of clinical trial applications from 19 June to 14 August 2017.

IMA - Icelandic Medicines Agency

14-11-2016

Deadline for submitting a clinical trial application (CTA) in 2016 is 9 December

Deadline for submitting a clinical trial application (CTA) in 2016 is 9 December

IMA will not confirm receipt of clinical trial applications or substantial amendments received after 9 December 2016 until after 2 January 2017.

IMA - Icelandic Medicines Agency

6-5-2016

Receipt of clinical trial applications (CTA) summer 2016

Receipt of clinical trial applications (CTA) summer 2016

Due to summer holiday the Icelandic Medicines Agency (IMA) will not confirm receipt of clinical trial applications from 20 June to 15 August 2016.

IMA - Icelandic Medicines Agency

19-12-2018


Orphan designation: (3R,3aS,9R,9aS,9bS)-3-((dimethylamino)methyl)-9-hydroxy-6,9-dimethyl-3,3a,4,5,7,8,9,9a-octahydroazuleno[4,5-b]furan-2(9bH)-one fumarate, Treatment of glioma, 24/08/2018, Positive

Orphan designation: (3R,3aS,9R,9aS,9bS)-3-((dimethylamino)methyl)-9-hydroxy-6,9-dimethyl-3,3a,4,5,7,8,9,9a-octahydroazuleno[4,5-b]furan-2(9bH)-one fumarate, Treatment of glioma, 24/08/2018, Positive

Orphan designation: (3R,3aS,9R,9aS,9bS)-3-((dimethylamino)methyl)-9-hydroxy-6,9-dimethyl-3,3a,4,5,7,8,9,9a-octahydroazuleno[4,5-b]furan-2(9bH)-one fumarate, Treatment of glioma, 24/08/2018, Positive

Europe - EMA - European Medicines Agency

26-11-2018

The 510(k) program has been strengthened and refined in many ways, especially in recent years, as the FDA’s Device Center has made a systematic, concerted effort to improve the program’s performance, predictability, efficiency and safety.

The 510(k) program has been strengthened and refined in many ways, especially in recent years, as the FDA’s Device Center has made a systematic, concerted effort to improve the program’s performance, predictability, efficiency and safety.

The 510(k) program has been strengthened and refined in many ways, especially in recent years, as the FDA’s Device Center has made a systematic, concerted effort to improve the program’s performance, predictability, efficiency and safety.

FDA - U.S. Food and Drug Administration

26-11-2018

Today, #FDA’s device center also posted performance report highlighting measures taken to increase predictability, transparency of 510(k) review process, incl. 50 final guidance documents on important medical device policy issues issued since 2009.  https

Today, #FDA’s device center also posted performance report highlighting measures taken to increase predictability, transparency of 510(k) review process, incl. 50 final guidance documents on important medical device policy issues issued since 2009. https

Today, #FDA’s device center also posted performance report highlighting measures taken to increase predictability, transparency of 510(k) review process, incl. 50 final guidance documents on important medical device policy issues issued since 2009. https://go.usa.gov/xPHdn 

FDA - U.S. Food and Drug Administration

21-9-2018

Scientific guideline:  Reflection paper on the use of aminopenicillins and their beta-lactamase inhibitor combinations in animals in the European Union: development of resistance and impact on human and animal health, draft: consultation open

Scientific guideline: Reflection paper on the use of aminopenicillins and their beta-lactamase inhibitor combinations in animals in the European Union: development of resistance and impact on human and animal health, draft: consultation open

The objective of this document is to review available information on the use of aminopenicillins and their beta-lactamase inhibitor combinations in veterinary medicines in the EU, their effect on the emergence of antimicrobial resistance (AMR) and the potential impact of resistance on human and animal health. The document provides information for the risk profiling, as recommended by the Antimicrobial Advice ad hoc Expert Group (AMEG) of the EMA.

Europe - EMA - European Medicines Agency

28-8-2018

EU/3/18/2055 (IQVIA RDS Ireland Limited)

EU/3/18/2055 (IQVIA RDS Ireland Limited)

EU/3/18/2055 (Active substance: (3R,3aS,9R,9aS,9bS)-3-((dimethylamino)methyl)-9-hydroxy-6,9-dimethyl-3,3a,4,5,7,8,9,9a-octahydroazuleno[4,5-b]furan-2(9bH)-one fumarate) - Orphan designation - Commission Decision (2018)5727 of Tue, 28 Aug 2018 European Medicines Agency (EMA) procedure number: EMA/OD/060/18

Europe -DG Health and Food Safety

2-8-2018

EU/3/18/2052 (Dicerna EU Limited)

EU/3/18/2052 (Dicerna EU Limited)

EU/3/18/2052 (Active substance: Synthetic double-stranded siRNA oligonucleotide directed against lactate dehydrogenase A mRNA and containing four modified nucleosides which form a ligand cluster of four N-acetylgalactosamine residues) - Orphan designation - Commission Decision (2018)5284 of Thu, 02 Aug 2018 European Medicines Agency (EMA) procedure number: EMA/OD/052/18

Europe -DG Health and Food Safety

29-5-2018

EU/3/14/1400 (Orphan Europe S.A.R.L.)

EU/3/14/1400 (Orphan Europe S.A.R.L.)

EU/3/14/1400 (Active substance: (1S,4R,5R,7S)-3,4-dibenzyl-2-oxo-6,8-dioxa-3-azabyciclo[3.2.1]octane-7-carboxylic acid-L-lysine) - Transfer of orphan designation - Commission Decision (2018)3402 of Tue, 29 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/185/14/T/01

Europe -DG Health and Food Safety